<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00261456</url>
  </required_header>
  <id_info>
    <org_study_id>05/MRE07/25</org_study_id>
    <secondary_id>CCR2598</secondary_id>
    <nct_id>NCT00261456</nct_id>
  </id_info>
  <brief_title>The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer</brief_title>
  <official_title>The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer: Targeted Screening in BRCA1/2 Mutation Carriers &amp; Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ronald and Rita McAulay Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Cancer Research, United Kingdom</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The IMPACT study is an international targeted prostate screening study of men at increased&#xD;
      prostate cancer risk due to the presence of known pathogenic mutations in BRCA1 and BRCA2&#xD;
      genes.&#xD;
&#xD;
      There are only approximately 150 men with a known BRCA1 or BRCA2 mutation in the UK. Research&#xD;
      has shown that these men are at an increased risk of developing prostate cancer but more&#xD;
      information is needed about the pathogenesis of prostate cancer in this defined group and the&#xD;
      role of screening in these men. The study will offer annual PSA screening to these men to&#xD;
      determine the incidence of prostate cancer in this group. The study will also look at new&#xD;
      markers of early prostate cancer in this cohort.&#xD;
&#xD;
      The power calculations for this study are 850 carriers and 850 controls (age-matched men&#xD;
      without BRCA1/2 mutations). It is therefore essential to gain international collaboration to&#xD;
      meet the target of recruiting 850 men with these known mutations and a control group of 850&#xD;
      men who have tested negative for a known familial mutation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate cancer is a significant public health problem. In the EU approximately 200,000 men&#xD;
      are diagnosed annually with prostate cancer. There are 24,000 cases per year in England and&#xD;
      Wales and 10,000 deaths. The incidence is increasing, even when screen-detected cancers are&#xD;
      considered, and within the next few years it will become the most common cancer in UK men.&#xD;
&#xD;
      that an alteration in the breast cancer predisposition genes BRCA1 and BRCA2, may predispose&#xD;
      to prostate cancer (PC) and this study will increase this evidence-base. There is some&#xD;
      evidence, at least in BRCA2 carriers, that the prostate cancer in these men may be more&#xD;
      aggressive and so earlier detection could theoretically reduce mortality. It has been&#xD;
      reported that unaffected individuals from families with multiple cases of PC show an&#xD;
      increased percentage of raised PSA levels, but the use of PSA level and its predictive value&#xD;
      in healthy males with BRCA1/2 mutations has not been studied. If PSA were to be used as a&#xD;
      screening tool in BRCA1/2 mutation carriers, we would need to gain a better understanding of&#xD;
      the pathogenesis of PC in these men and determine whether they have a different baseline PSA&#xD;
      profile compared with controls.&#xD;
&#xD;
      The high prevalence of hormone-dependent/secreting tumours such as breast, ovary and prostate&#xD;
      in BRCA1/2 carriers suggests an important role of hormones and their receptors in the&#xD;
      development of cancer. Androgens and androgen receptors are considered crucial elements in PC&#xD;
      pathogenesis. Therefore male sex hormones will be measured to determine the hormone profile&#xD;
      in BRCA1/2 carriers compared with a control group. There is strong evidence that BRCA1/2 play&#xD;
      an important role in DNA repair and cell cycling. Therefore, we will investigate&#xD;
      abnormalities of the metabolic processes in individuals with a BRCA1/2 mutation where cell&#xD;
      cycling may be abnormal. Analysis of proteins (proteomics) and metabolites (metabonomics) are&#xD;
      powerful approaches to identifying proteins and metabolites involved in cancer formation. The&#xD;
      analysis of the proteins and metabolites will enable us to investigate the effect of the&#xD;
      presence of a BRCA1/2 mutation and aid in the identification of new biomarkers for prostate&#xD;
      cancer.&#xD;
&#xD;
      The target population is a group of 850 males who carry a known pathogenic mutation in the&#xD;
      BRCA1/2 genes (500 BRCA1 and 350 BRCA2). These men will be recruited through genetics clinics&#xD;
      across the UK and the world. A control group of men who have tested negative for a known&#xD;
      pathogenic mutation that is running in their family will also be recruited through the&#xD;
      genetics clinics.&#xD;
&#xD;
      All participants will be invited to attend annually for 5 years for an appointment lasting&#xD;
      approximately 30 minutes during which they will discuss the study in detail before giving&#xD;
      their written consent agreeing to participate. They will have a 50ml blood sample taken and&#xD;
      be asked to provide a urine sample every year. They will also be required to complete a short&#xD;
      family and medical history questionnaire. These appointments will either take place at the&#xD;
      centre they are registered at, at the Royal Marsden Hospital, or in their own home depending&#xD;
      on the arrangements made with the collaborating consultant and patient preference.&#xD;
&#xD;
      The PSA level of all participants will be measured locally. If PSA is &gt;3.0ng/ml, a ten core&#xD;
      prostatic biopsy will be offered, carried out by a consultant urologist. Ten biopsies will be&#xD;
      used for diagnostic purposes, with two extra biopsy samples taken for research analysis with&#xD;
      the patients fully informed written consent prior to the procedure being carried out. If any&#xD;
      of the ten cores identify the presence of prostate cancer, they will receive treatment for&#xD;
      this as advised by their local centre. The PSA will be quality controlled by batch testing at&#xD;
      a reference lab. If the value locally was &lt;3.0ng/ml but is &gt;3ng/ml in the reference lab it&#xD;
      will be remeasured locally.&#xD;
&#xD;
      If high grade Prostatic Intraepithelial Neoplasia (PIN) is detected or if the sample is&#xD;
      inconclusive then a sextant biopsy repeated after 6 weeks will be recommended, in accordance&#xD;
      with the ERSPC protocol. If atypical acini are detected then immediate biopsy will be&#xD;
      undertaken.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Anticipated">February 2030</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1700</enrollment>
  <condition>Prostate Cancer in BRCA1 and BRCA2 Carriers</condition>
  <arm_group>
    <arm_group_label>BRCA1/2 carriers</arm_group_label>
    <description>Carriers of a BRCA1 or BRCA2 mutation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BRCA1/2/non Carriers</arm_group_label>
    <description>Do not carry a mutation in either the BRCA1 or 2 genes that has been found in other members of the family.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>PSA test</intervention_name>
    <description>Patients tested for their level of Prostate Specific Antigen.</description>
    <arm_group_label>BRCA1/2 carriers</arm_group_label>
    <arm_group_label>BRCA1/2/non Carriers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Prostate Biopsy</intervention_name>
    <description>A Prostate biopsy is given as an option to the patient if their PSA level is raised or at the end of 5 years screening.</description>
    <arm_group_label>BRCA1/2 carriers</arm_group_label>
    <arm_group_label>BRCA1/2/non Carriers</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, Serum, Plasma, Urine, Prostate tissue.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient that meets the eligibility criteria and maybe attending a genetics clinic at a&#xD;
        number of international centres that have gone through ethical approval.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male carriers of a known pathogenic BRCA1/2 mutations or men testing negative for a&#xD;
             known BRCA1/2 mutation in their family&#xD;
&#xD;
          -  Aged between 40-69 years old&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  No previous history of prostate cancer&#xD;
&#xD;
          -  No previous prostate biopsy for raised PSA&#xD;
&#xD;
          -  Absence of any psychological, familial, sociological or geographical situation&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
          -  Fully informed, written consent according to ICH/EU GCP and national/local regulations&#xD;
             before subject registration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous cancer with terminal prognosis of less than 5 years&#xD;
&#xD;
          -  Previous prostate cancer&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosalind A Eeles, FRCP FRCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Cancer Research and Royal Marsden Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Genetics Unit, Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://impact.icr.ac.uk/</url>
    <description>The IMPACT study website</description>
  </link>
  <link>
    <url>http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-at-screening-for-men-who-are-at-an-increased-risk-of-developing-prostate-cancer</url>
    <description>UK information point for eligible men</description>
  </link>
  <reference>
    <citation>Tischkowitz M, Eeles R; IMPACT study: Identification of Men with genetic predisposition to Prostate Cancer and its Clinical Treatment collaborators. Mutations in BRCA1 and BRCA2 and predisposition to prostate cancer. Lancet. 2003 Jul 5;362(9377):80; author reply 80.</citation>
    <PMID>12853213</PMID>
  </reference>
  <reference>
    <citation>Cremers RG, Eeles RA, Bancroft EK, Ringelberg-Borsboom J, Vasen HF, Van Asperen CJ; IMPACT Steering Committee, Schalken JA, Verhaegh GW, Kiemeney LA. The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers. Urol Oncol. 2015 May;33(5):202.e19-28. doi: 10.1016/j.urolonc.2015.01.018. Epub 2015 Mar 5.</citation>
    <PMID>25746941</PMID>
  </reference>
  <reference>
    <citation>Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A, Skytte AB, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Blanco I, Salinas M, Cook J, Rosario DJ, Buys S, Conner T, Ausems MG, Ong KR, Hoffman J, Domchek S, Powers J, Teixeira MR, Maia S, Foulkes WD, Taherian N, Ruijs M, Helderman-van den Enden AT, Izatt L, Davidson R, Adank MA, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman GJ, Zgajnar J, Tischkowitz M, Clowes VE, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady AF, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor DJ, Copakova L, Barwell J, Giri VN, Murthy V, Nicolai N, Teo SH, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra AV, Moynihan C, Rennert G, Suri M, Wilson P, Killick E; IMPACT Collaborators, Moss S, Eeles RA. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol. 2014 Sep;66(3):489-99. doi: 10.1016/j.eururo.2014.01.003. Epub 2014 Jan 15. Erratum in: Eur Urol. 2015 Jun;67(6):e126.</citation>
    <PMID>24484606</PMID>
  </reference>
  <reference>
    <citation>Killick E, Morgan R, Launchbury F, Bancroft E, Page E, Castro E, Kote-Jarai Z, Aprikian A, Blanco I, Clowes V, Domchek S, Douglas F, Eccles D, Evans DG, Harris M, Kirk J, Lam J, Lindeman G, Mitchell G, Pachter N, Selkirk C, Tucker K, Zgajnar J, Eeles R, Pandha H. Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men. Sci Rep. 2013;3:2059. doi: 10.1038/srep02059.</citation>
    <PMID>23792811</PMID>
  </reference>
  <reference>
    <citation>Whitaker HC, Kote-Jarai Z, Ross-Adams H, Warren AY, Burge J, George A, Bancroft E, Jhavar S, Leongamornlert D, Tymrakiewicz M, Saunders E, Page E, Mitra A, Mitchell G, Lindeman GJ, Evans DG, Blanco I, Mercer C, Rubinstein WS, Clowes V, Douglas F, Hodgson S, Walker L, Donaldson A, Izatt L, Dorkins H, Male A, Tucker K, Stapleton A, Lam J, Kirk J, Lilja H, Easton D; IMPACT Study Steering Committee; IMPACT Study Collaborators; UK GPCS Collaborators, Cooper C, Eeles R, Neal DE. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS One. 2010 Oct 13;5(10):e13363. doi: 10.1371/journal.pone.0013363.</citation>
    <PMID>20967219</PMID>
  </reference>
  <reference>
    <citation>Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, Taylor N, Chamberlain A, Pope J, Raghallaigh HN, Evans DG, Rothwell J, Maehle L, Grindedal EM, James P, Mascarenhas L, McKinley J, Side L, Thomas T, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Jensen TD, Osther PJS, Helfand BT, Genova E, Oldenburg RA, Cybulski C, Wokolorczyk D, Ong KR, Huber C, Lam J, Taylor L, Salinas M, Feliubadaló L, Oosterwijk JC, van Zelst-Stams W, Cook J, Rosario DJ, Domchek S, Powers J, Buys S, O'Toole K, Ausems MGEM, Schmutzler RK, Rhiem K, Izatt L, Tripathi V, Teixeira MR, Cardoso M, Foulkes WD, Aprikian A, van Randeraad H, Davidson R, Longmuir M, Ruijs MWG, Helderman van den Enden ATJM, Adank M, Williams R, Andrews L, Murphy DG, Halliday D, Walker L, Liljegren A, Carlsson S, Azzabi A, Jobson I, Morton C, Shackleton K, Snape K, Hanson H, Harris M, Tischkowitz M, Taylor A, Kirk J, Susman R, Chen-Shtoyerman R, Spigelman A, Pachter N, Ahmed M, Ramon Y Cajal T, Zgajnar J, Brewer C, Gadea N, Brady AF, van Os T, Gallagher D, Johannsson O, Donaldson A, Barwell J, Nicolai N, Friedman E, Obeid E, Greenhalgh L, Murthy V, Copakova L, Saya S, McGrath J, Cooke P, Rønlund K, Richardson K, Henderson A, Teo SH, Arun B, Kast K, Dias A, Aaronson NK, Ardern-Jones A, Bangma CH, Castro E, Dearnaley D, Eccles DM, Tricker K, Eyfjord J, Falconer A, Foster C, Gronberg H, Hamdy FC, Stefansdottir V, Khoo V, Lindeman GJ, Lubinski J, Axcrona K, Mikropoulos C, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Dudderidge T; IMPACT Study Collaborators, Offman J, Kote-Jarai Z, Vickers A, Lilja H, Eeles RA. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. Eur Urol. 2019 Dec;76(6):831-842. doi: 10.1016/j.eururo.2019.08.019. Epub 2019 Sep 16.</citation>
    <PMID>31537406</PMID>
  </reference>
  <reference>
    <citation>Mikropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MG, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden AT, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K; IMPACT study collaborators, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. Br J Cancer. 2018 Jan;118(2):266-276. doi: 10.1038/bjc.2017.429. Epub 2018 Jan 4. Erratum in: Br J Cancer. 2018 Mar 06;:.</citation>
    <PMID>29301143</PMID>
  </reference>
  <reference>
    <citation>Moynihan C, Bancroft EK, Mitra A, Ardern-Jones A, Castro E, Page EC, Eeles RA. Ambiguity in a masculine world: Being a BRCA1/2 mutation carrier and a man with prostate cancer. Psychooncology. 2017 Nov;26(11):1987-1993. doi: 10.1002/pon.4530. Epub 2017 Sep 18.</citation>
    <PMID>28812325</PMID>
  </reference>
  <results_reference>
    <citation>Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, Mitchell G, Lindeman GJ, Stapleton A, Suthers G, Evans DG, Cruger D, Blanco I, Mercer C, Kirk J, Maehle L, Hodgson S, Walker L, Izatt L, Douglas F, Tucker K, Dorkins H, Clowes V, Male A, Donaldson A, Brewer C, Doherty R, Bulman B, Osther PJ, Salinas M, Eccles D, Axcrona K, Jobson I, Newcombe B, Cybulski C, Rubinstein WS, Buys S, Townshend S, Friedman E, Domchek S, Ramon Y Cajal T, Spigelman A, Teo SH, Nicolai N, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Eyfjord J, Falconer A, Grönberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lilja H, Lubinski J, Melia J, Moynihan C, Peock S, Rennert G, Schröder F, Sibley P, Suri M, Wilson P, Bignon YJ, Strom S, Tischkowitz M, Liljegren A, Ilencikova D, Abele A, Kyriacou K, van Asperen C, Kiemeney L; IMPACT Study Collaborators, Easton DF, Eeles RA. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int. 2011 Jan;107(1):28-39. doi: 10.1111/j.1464-410X.2010.09648.x. Epub 2010 Sep 14.</citation>
    <PMID>20840664</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 1, 2005</study_first_submitted>
  <study_first_submitted_qc>December 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2005</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>BRCA1</keyword>
  <keyword>BRCA2</keyword>
  <keyword>prostate screening</keyword>
  <keyword>PSA</keyword>
  <keyword>prostate biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Genetic Predisposition to Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymised data can be applied for via the Data Access Committee</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

